"Ultra-low" doses of the drug rituximab may be enough to keep some patients' rheumatoid arthritis under control for several years, a new, preliminary study suggests.

Researchers found that among 118 patients, low doses of the drug were comparable to standard ones in controlling flare-ups for up to four years.

The findings, the researchers said, suggest that some patients can try low...